Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724425 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose Escalation Study of IPI-493
A Phase 1 study, sponsored by Infinity Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00724425: Clinical Trial Phase 1 study, sponsored by Infinity Pharmaceuticals.
NCT00724425 is a Phase 1 study that was terminated before completion, run by Infinity Pharmaceuticals. The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00724425, a Phase 1 study, was terminated before completion, sponsored by Infinity Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.
Interventions
- DRUG IPI-493
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Why NCT00724425 stopped before completion
NCT00724425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 1 intervention - of which IPI-493 is the first listed.
NCT00724425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00724425 about?
NCT00724425 is a clinical study titled "A Phase 1 Dose Escalation Study of IPI-493". IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.
What is the current status of trial NCT00724425?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2008-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00724425?
The interventions under investigation include: IPI-493 (DRUG).
Who is sponsoring clinical trial NCT00724425?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00724425's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia